Adherence

More than two-thirds of people with atopic dermatitis and skin of color experienced skin improvement in a first-of-its-kind lebrikizumab study

Retrieved on: 
Sunday, March 10, 2024
Diagnosis, Pigment, LLY, Weill Cornell Medicine, Atopic dermatitis, Health equity, Alaska Natives, Patient, Education, PDCA, Advocate, Diversity, Adherence, Immunology, Research, American Academy, Human, Weill Cornell Medical Center, Dermatitis, African, Skin, Safety, Lilly, Eli Lilly and Company, AAD, Health, IGA, Almirall, Pharmaceutical industry

In this study, treatment with lebrikizumab, an investigational medicine, showed improvement in skin clearance and itch relief.

Key Points: 
  • In this study, treatment with lebrikizumab, an investigational medicine, showed improvement in skin clearance and itch relief.
  • These late-breaking results from a Phase 3 study are being presented today at the American Academy of Dermatology (AAD) Annual Meeting.
  • "People with skin of color are disproportionately affected by atopic dermatitis, often experiencing more severe symptoms, a delay in diagnosis and a lengthier timeframe to find appropriate treatment.
  • "With these initial results, Lilly is taking a step toward investigating the needs of people with skin of color affected by atopic dermatitis."

Almirall Receives European Commission Approval of EBGLYSS® (lebrikizumab) for Moderate-to-Severe Atopic Dermatitis

Retrieved on: 
Friday, November 17, 2023
Health, Other Health, Other Science, General Health, Science, Pharmaceutical, Biotechnology, Allergic conjunctivitis, Itch, Adolescence, ALM, Adherence, Safety, Hope, European Commission, Advocate, Disease, Teaching hospital, Civil service commission, TCS, Patient, Week, Doctor of Philosophy, Conjunctivitis, Atopic dermatitis, BME, Eli Lilly and Company, MD, Skin, Almirall, Human, Pharmaceutical industry, Vaccine, Dermatology

“The arrival of novel biologic treatments is marking a new paradigm in the management of atopic dermatitis.

Key Points: 
  • “The arrival of novel biologic treatments is marking a new paradigm in the management of atopic dermatitis.
  • The approval of lebrikizumab represents a leap forward in our ability to provide patients with an effective therapeutic option with demonstrated safety profile.
  • Almirall has licensed the rights to develop and commercialize lebrikizumab for the treatment of dermatology indications, including atopic dermatitis, in Europe.
  • Almirall expects regulatory decisions for lebrikizumab in moderate-to-severe atopic dermatitis in additional European markets, including the United Kingdom and Switzerland.

Almirall: Nearly 80% of patients with moderate-to-severe atopic dermatitis maintained clear or almost-clear skin with lebrikizumab monthly maintenance dosing at two years

Retrieved on: 
Friday, October 20, 2023
Biotechnology, General Health, Other Health, Health, Pharmaceutical, Almirall, Lilly, Eli Lilly and Company, AD, Aes, Eli Lilly, Adherence, Conference, Maintenance, Addiction severity index, Conditional sentence, IGA, Shingles, Abstract, The New England Journal of Medicine, Conjunctivitis, British Journal of Dermatology, Atopic dermatitis, Patient, Pharmaceutical industry, Dermatology, Tree-adjoining grammar, EASI

In ADjoin, 62 percent of patients reported adverse events (AEs), most of which were mild or moderate in severity.

Key Points: 
  • In ADjoin, 62 percent of patients reported adverse events (AEs), most of which were mild or moderate in severity.
  • The most common side effects of lebrikizumab were conjunctivitis, injection site reactions and shingles (herpes zoster).
  • “Results from ADjoin reinforce the strong efficacy and safety profile of lebrikizumab seen in the other Phase 3 atopic dermatitis trials.
  • Lilly has exclusive rights for development and commercialization of lebrikizumab in the U.S. and the rest of the world outside Europe.

Almirall's Lebrikizumab Improves Signs and Symptoms of Moderate-to-Severe Atopic Dermatitis (AD) in Patients Inadequately Controlled With or Ineligible for Cyclosporine1

Retrieved on: 
Friday, October 13, 2023
Health, Managed Care, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Congress, EudraCT, Eli Lilly and Company, Knowledge, European Academies' Science Advisory Council, Advantage, CHMP, Abstract, Advocate, Ciclosporin, United Kingdom, BME, University, Week, Safety, ALM, Human, Disease, NRS, Psoriasis Area and Severity Index, Journal of the European Academy of Dermatology and Venereology, Almirall, Adolescence, Marketing, IGA, Adherence, AD, TCS, News, Overalls, EASI, Patient, Quality of life, Pharmaceutical industry, Dermatology, Venereology

Improvements in absolute skin response over 16 weeks for patients with moderate-to-severe AD treated with lebrikizumab or placebo were also shared.

Key Points: 
  • Improvements in absolute skin response over 16 weeks for patients with moderate-to-severe AD treated with lebrikizumab or placebo were also shared.
  • Almirall has licensed the rights to develop and commercialize lebrikizumab for the treatment of dermatology indications, including AD, in Europe.
  • Almirall expects regulatory decisions for lebrikizumab in moderate-to-severe AD in additional European markets, including the United Kingdom and Switzerland in 2024.
  • † More information about the Phase 3 studies: ADvocate 1: EudraCT Number 2019-002932-10; NCT04146363; ADvocate 2: EudraCT Number 2019-002933-12; NCT04178967; ADhere: EudraCT Number 2019-004300-34; NCT04250337

EBGLYSS® (lebrikizumab) Receives Positive CHMP Opinion for Moderate-to-severe Atopic Dermatitis

Retrieved on: 
Friday, September 15, 2023
Biotechnology, Other Health, Health, Pharmaceutical, Clinical Trials, Trinity College, Maintenance, Eczema Area and Severity Index, Disease, Civil service commission, AE, Week, Dermatitis, European Medicines Agency, Adherence, Committee for Medicinal Products for Human Use, Quality of life, Atopic dermatitis, Almirall, TCS, Committee, EMA, Trinity College Dublin, BME, Advocate, ALM, Patient, European, Adolescence, United Kingdom, Eli Lilly and Company, Itch, Hospital, AD, EudraCT, Conjunctivitis, EC, Human, Skin, European Commission, Safety, CHMP, Vaccine, Pharmaceutical industry, Dermatology

The positive CHMP opinion is now being reviewed by the European Commission (EC).

Key Points: 
  • The positive CHMP opinion is now being reviewed by the European Commission (EC).
  • “Atopic dermatitis, commonly known as atopic eczema, can have a profound impact on the quality of life for those it affects.
  • "The positive CHMP recommendation for EBGLYSS in moderate to severe AD represents a significant milestone in bringing a next-generation biologic therapy to people living with atopic dermatitis, providing a much needed additional treatment option.
  • Almirall has licensed the rights to develop and commercialize lebrikizumab for the treatment of dermatology indications, including atopic dermatitis, in Europe.

Mobiquity Signs Strategic Alliances to Bring Additional Demand to Its 1st Party Ad Serving Platform for Publishers

Retrieved on: 
Wednesday, July 26, 2023
Acceleration, Advertising, Interactivity, Cost per mille, SDA, Privacy, IAB, SSPS, Supply-side platform, CPM, Interactive Advertising Bureau, Adherence, Sales

The company’s proprietary AdHere platform , an innovative solution powered by forward-thinking architectural design, acts as the operational linchpin in this endeavor.

Key Points: 
  • The company’s proprietary AdHere platform , an innovative solution powered by forward-thinking architectural design, acts as the operational linchpin in this endeavor.
  • AdHere’s distinctive architecture is centered on empowering publishers to maximize the utilization of their first-party data.
  • Mobiquity CEO, Dean Julia, said, " These strategic partnerships mark a new era for Mobiquity as it continues to deliver compliant, effective, and privacy-centric advertising solutions.
  • We anticipate an acceleration in these trends as the digital advertising landscape evolves, with budgets increasingly pivoting towards compliant and privacy-preserving data solutions."

Almirall: Up to 73% of Atopic Dermatitis Patients Taking Lebrikizumab Had Improved or Cleared Skin on Face or Hands in New Analysis

Retrieved on: 
Monday, May 1, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Clinical Trials, The New England Journal of Medicine, AE, RAD, Face, Safety, Aes, Adherence, Atopic dermatitis, Dupilumab, Almirall, NEJM, Sample size determination, JAMA Dermatology, BJD, LEB, Advocate, Lilly, Patient, Common, Adolescence, Headache, Conjunctivitis, Abstract, Fertilizer, Pharmaceutical industry, Dermatology

This post-hoc analysis is based on individual patient trajectory data from two double-blind, placebo-controlled, monotherapy Phase 3 studies of lebrikizumab in adult and adolescent patients with moderate-to-severe AD.

Key Points: 
  • This post-hoc analysis is based on individual patient trajectory data from two double-blind, placebo-controlled, monotherapy Phase 3 studies of lebrikizumab in adult and adolescent patients with moderate-to-severe AD.
  • Safety among patients in ADvocate 1 and ADvocate 2 at one year was consistent with the induction phase of the trials and other lebrikizumab studies in AD, including ADhere.
  • Almirall has licensed the rights to develop and commercialize lebrikizumab for the treatment of dermatology indications, including AD, in Europe.
  • Lilly has exclusive rights for development and commercialization of lebrikizumab in the U.S. and the rest of the world outside Europe.

Up to 73% of Atopic Dermatitis Patients Taking Lilly's Lebrikizumab Had Improved or Cleared Skin on Face or Hands in New Analysis

Retrieved on: 
Monday, May 1, 2023
The New England Journal of Medicine, AE, RAD, Face, Safety, Aes, Adherence, Atopic dermatitis, Medicine, Dupilumab, Almirall, NEJM, Sample size determination, JAMA Dermatology, BJD, LEB, Advocate, Lilly, Patient, Common, Adolescence, Headache, Conjunctivitis, Abstract, Disease, Fertilizer, Pharmaceutical industry, Dermatology

This post-hoc analysis is based on individual patient trajectory data from two double-blind, placebo-controlled, monotherapy Phase 3 studies of lebrikizumab in adult and adolescent patients with moderate-to-severe AD.

Key Points: 
  • This post-hoc analysis is based on individual patient trajectory data from two double-blind, placebo-controlled, monotherapy Phase 3 studies of lebrikizumab in adult and adolescent patients with moderate-to-severe AD.
  • Safety among patients in ADvocate 1 and ADvocate 2 at one year was consistent with the induction phase of the trials and other lebrikizumab studies in AD, including ADhere.
  • Most AEs across the two studies were mild or moderate in severity, nonserious, and did not lead to treatment discontinuation.
  • Almirall has licensed the rights to develop and commercialize lebrikizumab for the treatment of dermatology indications, including AD, in Europe.

Almirall announces EMA acceptance for filing of Marketing Authorization Application (MAA) for lebrikizumab in atopic dermatitis

Retrieved on: 
Friday, October 28, 2022
Skin, Phase, MAA, Atopic dermatitis, Company, Dermatology, AD, Marketing, Prevalence, Safety, Adherence, Advocate, Eli Lilly and Company, File, Patient, Almirall, Adult, Adolescence, Week, TCS, Eczema Area and Severity Index, EudraCT, Psoriasis Area and Severity Index, EMA, ALM, Vaccine, Pharmaceutical industry, EU

"Today marks the first step of the regulatory process in Europe of lebrikizumab, which we believe it has the potential to become a best-in-class treatment for atopic dermatitis.

Key Points: 
  • "Today marks the first step of the regulatory process in Europe of lebrikizumab, which we believe it has the potential to become a best-in-class treatment for atopic dermatitis.
  • Upon approvalby the EMA, patients with AD would have a new treatment option with a favourable safety and efficacy profile.
  • Almirall has licensed the rights to develop and commercialize lebrikizumab for the treatment of dermatology indications, including AD, in Europe.
  • [*] More information about the Phase III studies: ADvocate 1: EudraCT Number 2019-002932-10; NCT04146363; ADvocate 2: EudraCT Number 2019-002933-12; NCT04178967; Adhere: EudraCT Number 2019-004300-34; NCT04250337

Bay Area Youth Entrepreneurs Advance to National Pitch Competition

Retrieved on: 
Thursday, June 2, 2022
Seed, EY, Shark Tank, NFTE, CEO, Lincoln High School, Capitalism, Entrepreneurship, Adherence, Growth, Student, GLOBE, National, Network, Communication, Tutoring, Creative industries, EBay, Nationals

The winners of the Network for Teaching Entrepreneurship (NFTE) Bay Area Youth Entrepreneurship Challenge Finals will do just that, taking their business ideas to New York mid-October to vie for the title of National Champion and prizes from a pool of $18,000.

Key Points: 
  • The winners of the Network for Teaching Entrepreneurship (NFTE) Bay Area Youth Entrepreneurship Challenge Finals will do just that, taking their business ideas to New York mid-October to vie for the title of National Champion and prizes from a pool of $18,000.
  • Participating students presented their original business ideas to a panel of esteemed judges, who named three winners.
  • Each young entrepreneurs innovative idea signifies an opportunity to address key challenges facing communities around the globe.
  • To learn more about how we are promoting inclusive capitalism and building the next generation of diverse entrepreneurs, visit www.nfte.com .